NYMALIZE |
NIMOTOP |
NIMODIPINE |
BAY-E-9736 |
ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE |
NIMODIPINUM |
2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-BETA-METHOXYETHYL ESTER 5-ISOPROPYL ESTER |
NIMODIPINO |
2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-Β-METHOXYETHYL ESTER 5-ISOPROPYL ESTER |
BAY E 9736 |
ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE |
NIMOTOP® |
chemidplus:66085-59-4 |
rxcui:7426 |
drugbank:00393 |
pubchem.compound:4497 |
chembl:CHEMBL1428 |
Drug Categories | selective calcium channel blockers with mainly vascular effects |
Drug Categories | nicotinic acids |
Drug Categories | dihydropyridines |
FDA Approval | 1988 |
Drug Class | small molecule |
Drug Indications | Vasodilator Agents |
Drug Indications | Antihypertensive Agents |
Year of Approval | 1988 |
Drug Class | vasodilator agents |
Drug Class | antihypertensive agents |
Drug Groups | investigational |
Drug Categories | agents causing hyperkalemia |
Drug Categories | antiarrhythmic agents |
Drug Categories | bradycardia-causing agents |
Drug Categories | calcium-regulating hormones and agents |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | moderate risk qtc-prolonging agents |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | qtc prolonging agents |
Drug Categories | vasodilating agents |
blocker (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Specific Action of the Ligand | Antagonist |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
Direct Interaction? | False |
blocker (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Details of Interaction | inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain |
Endogenous Drug? | False |
n/a |
Novel drug target | Established target |
Trial Name | - |
activator (activating) |
Endogenous Drug? | False |
Specific Action of the Ligand | Potentiation |
NIMODIPINE | DrugBank Drug Name |
66085-59-4 | CAS Number |
Nimodipine | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
NIMODIPINE | Primary Drug Name |
Drug Class | antihypertensive agents |
Drug Class | vasodilator agents |
Year of Approval | 1988 |
Drug Indications | Antihypertensive Agents |
Drug Indications | Vasodilator Agents |
Drug Class | small molecule |
CHEMBL1428 | ChEMBL Drug ID |
C692 | NCI drug code |
NIMODIPINE | GuideToPharmacology Ligand Name |
D0XN1F | TTD Drug ID |